Take a deeper dive

Events

Webinar: Addressing the Challenges of Drug Discovery and Delivery for Combination Peptide Therapeutics

On May 1st, Nuventra’s Mark Bush PhD, and Intarcia Therapeutics’ Paul L. Feldman PhD, will lead a webinar titled “Addressing the Challenges of Drug Discovery and Delivery for Combination Peptide Therapeutics.

There has been growing interest and activity in the use of peptide therapeutics to treat a variety of human diseases.  This webinar will present approaches to discover, optimize, assess, and deliver combination peptide therapeutics for treatment of metabolic diseases. Additionally, various considerations to deliver peptide combinations for efficient development and optimal patient benefit and adherence will be presented.

The presentation also will cover key pharmacokinetic considerations in the development of peptide drugs with a focus on factors that affect the absorption, distribution, and elimination of peptide drugs.

The webinar is free of charge  Register here.


Meet the Speakers

Mark Bush, PhD, RPh 
Nuventra Inc. | Associate Vice President, Clinical Pharmacology & Pharmacokinetics

Dr. Bush has over 19 years of experience in Clinical Pharmacology and Pharmacokinetics with a particular focus in clinical pharmacology study design and interpretation as well as PK and PK/PD modeling and simulation. His therapeutic concentrations include Endocrinology and Metabolism in early phases of development. Dr. Bush has worked on approximately 2 NDAs, 2 BLAs, 4 INDs, and over 100 PK and Population PK analyses.

Paul L. Feldman, PhD
Intarcia Therapeutics | Head of Discovery and Translational Medicine

Dr. Feldman joined Intarcia in September 2015 as Head of Discovery and Translational Medicine following Intarcia’s acquisition of Phoundry Pharmaceuticals, Inc., a peptide therapeutic discovery company, where he was a co-founder and CEO. Dr. Feldman’s accomplishments include: contributing to the discovery and development of multiple medicines, leading national and international multi-disciplinary discovery and early development groups, plus much more.

Back